Protein Kinase Inhibitors for Direct Fibroblast to OPC Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating oligodendrocyte progenitor cells for treating CNS disorders and spinal cord injuries face challenges such as safety concerns due to tumorgenesis and immune rejection, and require lengthy procedures involving viral vector integration for direct somatic cell conversion.
Innovation Solution
The use of protein kinase inhibitors like ROCK, AKT/mTOR, PI3K, and FAK inhibitors, or immunosuppressants to convert fibroblast cells into oligodendrocyte progenitor cells without the need for transcription factors, facilitating rapid and efficient production suitable for autologous transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transcription factors are used for direct somatic cell conversion, then neural cells can be generated, but the procedure becomes lengthy and unsafe due to viral vector integration into the genome
Solution Approach 1:
The patent extracts and removes transcription factors from the conversion process, using small molecule inhibitors instead. This eliminates the need for viral vector integration while maintaining the ability to induce neural cell conversion, thereby improving safety without significantly extending procedure time.
Solution Approach 2:
The patent replaces the genetic manipulation mechanism (transcription factors delivered via viral vectors) with a chemical mechanism (small molecule inhibitors). This substitution eliminates genome integration risks while achieving the same cellular reprogramming effect, resolving the safety-time contradiction.
2Quantity of substance
If hESC or hiPSC are used for neural cell generation, then large quantities of cells can be produced, but safety issues arise due to potential tumorgenesis and immune rejection
Solution Approach 1:
The patent extracts neural cells directly from patient somatic cells through chemical inhibition, bypassing the pluripotent cell stage entirely. This eliminates the risk of tumorgenesis associated with hESC/hiPSC while still producing sufficient quantities of neural cells for transplantation.
Solution Approach 2:
Instead of following the conventional path from somatic cells to pluripotent cells to neural cells, the patent inverts the approach by directly converting somatic cells to neural cells using chemical inhibitors. This reverse pathway avoids the safety issues of pluripotent cell intermediates while maintaining cell quantity production.
3Adaptability or versatility
If direct fibroblast-OPC conversion is performed using transcription factors, then autologous transplantation is enabled, but the process remains unsafe due to viral vector integration
Solution Approach 1:
The patent replaces viral vector-based transcription factor delivery with small molecule inhibitor treatment. This substitution maintains the autologous transplantation capability while eliminating the safety risks of viral integration, allowing direct fibroblast to OPC conversion without genetic modification.
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3C
AI summary
Usage of a protein kinase inhibitor in preparing a neural cell from a differentiated non-neural cell is provided.